Table 1 Patient demographic characteristics
|  | Placebo (N = 27) | Namilumab | ||
|---|---|---|---|---|
20 mg (N = 28) | 80 mg (N = 25) | 150 mg (N = 28) | ||
Age, years | 47.2 ± 13.45 | 46.1 ± 10.07 | 49.0 ± 9.60 | 51.3 ± 14.13 |
Female | 23 (85.2) | 22 (78.6) | 17 (68.0) | 22 (78.6) |
Race | ||||
 Asian | 6 (22.2) | 4 (14.3) | 3 (12.0) | 5 (17.9) |
 White | 21 (77.8) | 24 (85.7) | 22 (88.0) | 22 (78.6) |
 Multiracial | 0 | 0 | 0 | 1 (3.6) |
BMI, kg/m2 | 23.75 ± 5.542 | 24.91 ± 5.210 | 27.16 ± 5.605 | 25.92 ± 6.313 |
BMI categories | ||||
 < 30 kg/m2 | 24 (88.9) | 23 (82.1) | 16 (64.0) | 22 (78.6) |
 ≥ 30 kg/m2 | 3 (11.1) | 5 (17.9) | 9 (36.0) | 6 (21.4) |
Smoking classification | ||||
 Nonsmoker | 16 (59.3) | 19 (67.9) | 18 (72.0) | 18 (64.3) |
 Ex-smoker | 6 (22.2) | 5 (17.9) | 5 (20.0) | 6 (21.4) |
 Current smoker | 5 (18.5) | 4 (14.3) | 2 (8.0) | 4 (14.3) |
Region | ||||
 Ex-Japan | 23 (85.2) | 24 (85.7) | 22 (88.0) | 23 (82.1) |
 Japan | 4 (14.8) | 4 (14.3) | 3 (12.0) | 5 (17.9) |